Close Cookie Popup

Cookie Preferences

By clicking “Accept All”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage and assist in our marketing efforts as outlined in our cookie policy.

NLC completes first close of €100 million health impact fund

https://nlc-health.webflow.io/news/nlc-completes-first-close-of-eu100m-health-impact-fund

By

Nanna Liebregt

May 2024

•

5 min read

By

Nanna Liebregt

May 2024

•

5 min read

Read article on external website

Share this post

News

Insights

Nina Rijnders: Impact investing for philanthropic fund (In Dutch)

Nina Rijnders: Impact investing for philanthropic fund (In Dutch)

Nina Rijnders: Impact investing for philanthropic fund (In Dutch)

SERDA Therapeutics Announces Completion of First Phase 1 Clinical Study of SN514

SERDA Therapeutics Announces Completion of First Phase 1 Clinical Study of SN514

SERDA Therapeutics Announces Completion of First Phase 1 Clinical Study of SN514

Introducing Exolvo: NLC Health Ventures launches new early-stage drug delivery company

Venture launches

Introducing Exolvo: NLC Health Ventures launches new early-stage drug delivery company

Venture launches

Introducing Exolvo: NLC Health Ventures launches new early-stage drug delivery company

Dutch health insurer VGZ invests €6 million in NLC Health Ventures

Dutch health insurer VGZ invests €6 million in NLC Health Ventures

Dutch health insurer VGZ invests €6 million in NLC Health Ventures

NLC was named the Number 1 Most Active Early Stage Investor in Healthcare in Europe by Financial Times’ Sifted

NLC was named the Number 1 Most Active Early Stage Investor in Healthcare in Europe by Financial Times’ Sifted

NLC was named the Number 1 Most Active Early Stage Investor in Healthcare in Europe by Financial Times’ Sifted

NLC venture Altach secures €1.2 million investment to transform treatments for cartilage injuries

NLC venture Altach secures €1.2 million investment to transform treatments for cartilage injuries

NLC venture Altach secures €1.2 million investment to transform treatments for cartilage injuries

AI Healthtech start-up MindAffect raises €1.1 million to transform hearing diagnostics

AI Healthtech start-up MindAffect raises €1.1 million to transform hearing diagnostics

AI Healthtech start-up MindAffect raises €1.1 million to transform hearing diagnostics

IPD secures funding of €2.1 million to initiate its first-in-human trials for prosthetic joint infections

IPD secures funding of €2.1 million to initiate its first-in-human trials for prosthetic joint infections

IPD secures funding of €2.1 million to initiate its first-in-human trials for prosthetic joint infections

Introducing Aerion Bioscience: A new era of cancer screening

Venture launches

Introducing Aerion Bioscience: A new era of cancer screening

Venture launches

Introducing Aerion Bioscience: A new era of cancer screening

CUIP and NLC Health Ventures signed a MoU to bring cutting-edge innovations to life

CUIP and NLC Health Ventures signed a MoU to bring cutting-edge innovations to life

CUIP and NLC Health Ventures signed a MoU to bring cutting-edge innovations to life

POROUS wins innovation award

POROUS wins innovation award

POROUS wins innovation award

Ansana secures a €850,000 investment

Ansana secures a €850,000 investment

Ansana secures a €850,000 investment

Introducing LiftYa: Stability with motion

Venture launches

Introducing LiftYa: Stability with motion

Venture launches

Introducing LiftYa: Stability with motion

Introducing StarTric: Transcatheter tricuspid heart valve repair

Venture launches

Introducing StarTric: Transcatheter tricuspid heart valve repair

Venture launches

Introducing StarTric: Transcatheter tricuspid heart valve repair

Introducing Amotio: Revolutionising orthopaedic revision surgery: An innovative approach to major joint implant revisions

Venture launches

Introducing Amotio: Revolutionising orthopaedic revision surgery: An innovative approach to major joint implant revisions

Venture launches

Introducing Amotio: Revolutionising orthopaedic revision surgery: An innovative approach to major joint implant revisions

NLC was named the Number 1 Most Active Early Stage Investor in Healthcare in Europe by Financial Times’ Sifted.

NLC was named the Number 1 Most Active Early Stage Investor in Healthcare in Europe by Financial Times’ Sifted.

NLC was named the Number 1 Most Active Early Stage Investor in Healthcare in Europe by Financial Times’ Sifted.

Introducing our newest venture ChARM: Empowering low-resource healthcare professionals around the world

Venture launches

Introducing our newest venture ChARM: Empowering low-resource healthcare professionals around the world

Venture launches

Introducing our newest venture ChARM: Empowering low-resource healthcare professionals around the world

Introducing our newest venture: Asclepius

Venture launches

Introducing our newest venture: Asclepius

Venture launches

Introducing our newest venture: Asclepius

Introducing our venture Nilocas: A cardiac device for the detection of coronary artery disease

Venture launches

Introducing our venture Nilocas: A cardiac device for the detection of coronary artery disease

Venture launches

Introducing our venture Nilocas: A cardiac device for the detection of coronary artery disease

Porous nominated for the Innovation Award Berlin Brandenburg

Porous nominated for the Innovation Award Berlin Brandenburg

Porous nominated for the Innovation Award Berlin Brandenburg